CYTOGENIX!!! Kursverdoppler oder sogar noch mehr!!??!! - 500 Beiträge pro Seite
eröffnet am 16.04.04 17:07:45 von
neuester Beitrag 04.05.04 14:18:53 von
neuester Beitrag 04.05.04 14:18:53 von
Beiträge: 5
ID: 848.150
ID: 848.150
Aufrufe heute: 0
Gesamt: 408
Gesamt: 408
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 08.05.24, 11:56 | 477 | |
| gestern 18:51 | 165 | |
| gestern 22:50 | 162 | |
| gestern 20:31 | 158 | |
| gestern 22:33 | 151 | |
| 11.05.24, 11:52 | 122 | |
| vor 1 Stunde | 112 | |
| gestern 23:22 | 106 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 0,2170 | +3,33 | 48 | |||
| 2. | 2. | 18.763,00 | -0,01 | 44 | |||
| 3. | 3. | 168,47 | -2,04 | 28 | |||
| 4. | 4. | 0,1640 | 0,00 | 22 | |||
| 5. | 6. | 0,2980 | -3,87 | 17 | |||
| 6. | 5. | 2,5600 | -6,91 | 16 | |||
| 7. | 7. | 898,78 | +1,27 | 13 | |||
| 8. | 8. | 10,320 | 0,00 | 12 |
Feedback
Startet diese Aktie bald durch? Bereits vor einem Monat von Small Cap Research empfohlen; mit sehr guten Chancen auf $1,16 und mehr!
ist da was im busch?
in usa +15%
in usa +15%
sollte langsam mal in die gänge kommen, das teil!
Cytogenix, Inc.`s (CYGX.OB) Herpes Treatment Product to Be Tested By Phanuel Pursuits India, L.L.C.
ARLINGTON, Texas, April 30 /PRNewswire/ -- Phanuel Pursuits, L.L.C., in conjunction with Phanuel Pursuits India, L.L.C., has filed an application to conduct human clinical studies in India utilizing a blind study of patients suffering from both Herpes Simplex I (cold sores and fever blisters) and Herpes Simplex II (genital herpes). The studies are designed to test the safety and efficacy of an innovative topically applied Herpes Treatment Cream patented by CytoGenix, Inc.(NASDAQ-OTCBB:CYGX) (OTC Bulletin Board: CYGX), a biomedical research company based in Houston, Texas. The treatment uses single strand DNA technology, a cutting edge gene therapy, to treat Herpes Simplex I and II. This treatment is unique because it destroys the herpes virus`s ability to reproduce, which ultimately leaves the patient symptom free.
"Clinical studies are the last step in the pharmaceutical product introduction process," states David Lane, President of Phanuel Pursuits, L.L.C. "We anticipate product introduction as soon as the studies are completed and approval for sale is obtained. We have chosen Dr. Prabhakara Chaturvedula to serve as President of Phanuel Pursuits India, L.L.C. Dr. Chaturvedula is a U.S. trained physician with over twenty years experience in the medical field. He is highly educated and considered an expert in the medical field. Once we learned that Dr. Chaturvedula had returned to his home in Bangalore, India to provide free medical treatment to those in great need, he became the obvious choice for the job." Dr. Chaturvedula, with a team of research scientists from CytoGenix(NASDAQ-OTCBB:CYGX) acting as technical consultants to him, will oversee the clinical studies for Phanuel Pursuits India, L.L.C.
Herpes is a problem world-wide and has truly become an epidemic. Genital herpes is the leading cause of child blindness. Over a billion dollars is spent annually in treating herpes symptoms (mostly genital herpes) in the United States today. CytoGenix`s(NASDAQ-OTCBB:CYGX) DNA based, patented technology has shown great promise in different tests to date. The herpes treatments currently in use today only treat the symptoms of herpes, not the cause, making CytoGenix`s(NASDAQ-OTCBB:CYGX) product truly unique.
SOURCE Phanuel Pursuits, L.L.C.
-0- 04/30/2004
/CONTACT: David Lane of Phanuel Pursuits, L.L.C., +1-940-704-5736/
(CYGX)
CO: Phanuel Pursuits, L.L.C.; Phanuel Pursuits India, L.L.C.; CytoGenix, Inc.(NASDAQ-OTCBB:CYGX)
ST: Texas, India
IN: HEA MTC BIO OTC
SU:
AW-CD
-- DAF016 --
1287 04/30/200411:14 EDThttp://www.prnewswire.com
Cytogenix, Inc.`s (CYGX.OB) Herpes Treatment Product to Be Tested By Phanuel Pursuits India, L.L.C.
ARLINGTON, Texas, April 30 /PRNewswire/ -- Phanuel Pursuits, L.L.C., in conjunction with Phanuel Pursuits India, L.L.C., has filed an application to conduct human clinical studies in India utilizing a blind study of patients suffering from both Herpes Simplex I (cold sores and fever blisters) and Herpes Simplex II (genital herpes). The studies are designed to test the safety and efficacy of an innovative topically applied Herpes Treatment Cream patented by CytoGenix, Inc.(NASDAQ-OTCBB:CYGX) (OTC Bulletin Board: CYGX), a biomedical research company based in Houston, Texas. The treatment uses single strand DNA technology, a cutting edge gene therapy, to treat Herpes Simplex I and II. This treatment is unique because it destroys the herpes virus`s ability to reproduce, which ultimately leaves the patient symptom free.
"Clinical studies are the last step in the pharmaceutical product introduction process," states David Lane, President of Phanuel Pursuits, L.L.C. "We anticipate product introduction as soon as the studies are completed and approval for sale is obtained. We have chosen Dr. Prabhakara Chaturvedula to serve as President of Phanuel Pursuits India, L.L.C. Dr. Chaturvedula is a U.S. trained physician with over twenty years experience in the medical field. He is highly educated and considered an expert in the medical field. Once we learned that Dr. Chaturvedula had returned to his home in Bangalore, India to provide free medical treatment to those in great need, he became the obvious choice for the job." Dr. Chaturvedula, with a team of research scientists from CytoGenix(NASDAQ-OTCBB:CYGX) acting as technical consultants to him, will oversee the clinical studies for Phanuel Pursuits India, L.L.C.
Herpes is a problem world-wide and has truly become an epidemic. Genital herpes is the leading cause of child blindness. Over a billion dollars is spent annually in treating herpes symptoms (mostly genital herpes) in the United States today. CytoGenix`s(NASDAQ-OTCBB:CYGX) DNA based, patented technology has shown great promise in different tests to date. The herpes treatments currently in use today only treat the symptoms of herpes, not the cause, making CytoGenix`s(NASDAQ-OTCBB:CYGX) product truly unique.
SOURCE Phanuel Pursuits, L.L.C.
-0- 04/30/2004
/CONTACT: David Lane of Phanuel Pursuits, L.L.C., +1-940-704-5736/
(CYGX)
CO: Phanuel Pursuits, L.L.C.; Phanuel Pursuits India, L.L.C.; CytoGenix, Inc.(NASDAQ-OTCBB:CYGX)
ST: Texas, India
IN: HEA MTC BIO OTC
SU:
AW-CD
-- DAF016 --
1287 04/30/200411:14 EDThttp://www.prnewswire.com
Cytogenix, Inc.`s (CYGX.OB) Herpes Treatment Product to Be Tested By Phanuel Pursuits India, L.L.C.
ARLINGTON, Texas, April 30 /PRNewswire/ -- Phanuel Pursuits, L.L.C., in conjunction with Phanuel Pursuits India, L.L.C., has filed an application to conduct human clinical studies in India utilizing a blind study of patients suffering from both Herpes Simplex I (cold sores and fever blisters) and Herpes Simplex II (genital herpes). The studies are designed to test the safety and efficacy of an innovative topically applied Herpes Treatment Cream patented by CytoGenix, Inc.(NASDAQ-OTCBB:CYGX) (OTC Bulletin Board: CYGX), a biomedical research company based in Houston, Texas. The treatment uses single strand DNA technology, a cutting edge gene therapy, to treat Herpes Simplex I and II. This treatment is unique because it destroys the herpes virus`s ability to reproduce, which ultimately leaves the patient symptom free.
"Clinical studies are the last step in the pharmaceutical product introduction process," states David Lane, President of Phanuel Pursuits, L.L.C. "We anticipate product introduction as soon as the studies are completed and approval for sale is obtained. We have chosen Dr. Prabhakara Chaturvedula to serve as President of Phanuel Pursuits India, L.L.C. Dr. Chaturvedula is a U.S. trained physician with over twenty years experience in the medical field. He is highly educated and considered an expert in the medical field. Once we learned that Dr. Chaturvedula had returned to his home in Bangalore, India to provide free medical treatment to those in great need, he became the obvious choice for the job." Dr. Chaturvedula, with a team of research scientists from CytoGenix(NASDAQ-OTCBB:CYGX) acting as technical consultants to him, will oversee the clinical studies for Phanuel Pursuits India, L.L.C.
Herpes is a problem world-wide and has truly become an epidemic. Genital herpes is the leading cause of child blindness. Over a billion dollars is spent annually in treating herpes symptoms (mostly genital herpes) in the United States today. CytoGenix`s(NASDAQ-OTCBB:CYGX) DNA based, patented technology has shown great promise in different tests to date. The herpes treatments currently in use today only treat the symptoms of herpes, not the cause, making CytoGenix`s(NASDAQ-OTCBB:CYGX) product truly unique.
SOURCE Phanuel Pursuits, L.L.C.
-0- 04/30/2004
/CONTACT: David Lane of Phanuel Pursuits, L.L.C., +1-940-704-5736/
(CYGX)
CO: Phanuel Pursuits, L.L.C.; Phanuel Pursuits India, L.L.C.; CytoGenix, Inc.(NASDAQ-OTCBB:CYGX)
ST: Texas, India
IN: HEA MTC BIO OTC
SU:
AW-CD
-- DAF016 --
1287 04/30/200411:14 EDThttp://www.prnewswire.com
ARLINGTON, Texas, April 30 /PRNewswire/ -- Phanuel Pursuits, L.L.C., in conjunction with Phanuel Pursuits India, L.L.C., has filed an application to conduct human clinical studies in India utilizing a blind study of patients suffering from both Herpes Simplex I (cold sores and fever blisters) and Herpes Simplex II (genital herpes). The studies are designed to test the safety and efficacy of an innovative topically applied Herpes Treatment Cream patented by CytoGenix, Inc.(NASDAQ-OTCBB:CYGX) (OTC Bulletin Board: CYGX), a biomedical research company based in Houston, Texas. The treatment uses single strand DNA technology, a cutting edge gene therapy, to treat Herpes Simplex I and II. This treatment is unique because it destroys the herpes virus`s ability to reproduce, which ultimately leaves the patient symptom free.
"Clinical studies are the last step in the pharmaceutical product introduction process," states David Lane, President of Phanuel Pursuits, L.L.C. "We anticipate product introduction as soon as the studies are completed and approval for sale is obtained. We have chosen Dr. Prabhakara Chaturvedula to serve as President of Phanuel Pursuits India, L.L.C. Dr. Chaturvedula is a U.S. trained physician with over twenty years experience in the medical field. He is highly educated and considered an expert in the medical field. Once we learned that Dr. Chaturvedula had returned to his home in Bangalore, India to provide free medical treatment to those in great need, he became the obvious choice for the job." Dr. Chaturvedula, with a team of research scientists from CytoGenix(NASDAQ-OTCBB:CYGX) acting as technical consultants to him, will oversee the clinical studies for Phanuel Pursuits India, L.L.C.
Herpes is a problem world-wide and has truly become an epidemic. Genital herpes is the leading cause of child blindness. Over a billion dollars is spent annually in treating herpes symptoms (mostly genital herpes) in the United States today. CytoGenix`s(NASDAQ-OTCBB:CYGX) DNA based, patented technology has shown great promise in different tests to date. The herpes treatments currently in use today only treat the symptoms of herpes, not the cause, making CytoGenix`s(NASDAQ-OTCBB:CYGX) product truly unique.
SOURCE Phanuel Pursuits, L.L.C.
-0- 04/30/2004
/CONTACT: David Lane of Phanuel Pursuits, L.L.C., +1-940-704-5736/
(CYGX)
CO: Phanuel Pursuits, L.L.C.; Phanuel Pursuits India, L.L.C.; CytoGenix, Inc.(NASDAQ-OTCBB:CYGX)
ST: Texas, India
IN: HEA MTC BIO OTC
SU:
AW-CD
-- DAF016 --
1287 04/30/200411:14 EDThttp://www.prnewswire.com
Die kürzlich bekannt gegebene Kooperation mit der indischen Pharmafirma zeigt, dass CytoGenix weiter auf dem richtigen Weg ist. Phanuel Pursuits, L.L.C. ist ein renommiertes Unternehmen in Indien, das schon über 20 Jahre im Business ist. CytoGenix hat damit einen weiteren starken Partner für sein Herpes Produkt gewinnen können.
Laut Lawrence Wunderlich (CFO von CYGX - der übrigens hervorragend Deutsch spricht...) soll demnächst ein Vertrag mit einer renommierten Investment Bank abgeschlossen werden, der die Finanzierung der notwendigen Forschungen sichert.
Wenn die Pressemitteilung dazu bekannt gegeben wird, gibt es sicher kein Halten mehr!
Laut Lawrence Wunderlich (CFO von CYGX - der übrigens hervorragend Deutsch spricht...) soll demnächst ein Vertrag mit einer renommierten Investment Bank abgeschlossen werden, der die Finanzierung der notwendigen Forschungen sichert.
Wenn die Pressemitteilung dazu bekannt gegeben wird, gibt es sicher kein Halten mehr!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 48 | ||
| 44 | ||
| 28 | ||
| 22 | ||
| 17 | ||
| 16 | ||
| 13 | ||
| 12 | ||
| 10 | ||
| 10 |
| Wertpapier | Beiträge | |
|---|---|---|
| 9 | ||
| 8 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 5 | ||
| 5 |
